A Better, Less
Invasive Option

A Better, Less
Invasive Option

Guide your symptomatic severe AS patients – including low-risk patients – to the superior* treatment1-3

PARTNER 3 Trial demonstrated unprecedented clinical outcomes.2,4-5
At 1 year, SAPIEN 3 TAVI demonstrated 3X lower risk of death and disabling stroke compared with surgery.2

from death or disabling stroke
at 1 year with SAPIEN 3 TAVI vs 97.1% for surgery (P = 0.03)
Compared to 2.9% death or disabling stroke at 1 year for surgery (P = 0.03)

PARTNER 3 Trial: Primary endpoint

30 Days 1 Year
SAPIEN 3 TAVI
(n = 496)		 Surgery
(n = 454)		 SAPIEN 3 TAVI
(n = 496)		 Surgery
(n = 454)		 P-Value
All-Cause Death 0.4% 1.1% 1.0% 2.5% P = 0.09
All Stroke 0.6% 2.4% 1.2% 3.1% P = 0.04
Rehospitalization** 3.4% 6.5% 7.3% 11.0% P = 0.046

All-cause death, stroke, and rehospitalization at 1 year: 8.5% TAVI vs. 15.1% for surgery (P = 0.001)

30 Days
SAPIEN 3 TAVI
(n = 496)		 Surgery
(n = 454)
All-Cause Death 0.4% 1.1%
All Stroke 0.6% 2.4%
Rehospitalization** 3.4% 6.5%

All-cause death, stroke, and rehospitalization at 1 year: 8.5% TAVI vs. 15.1% for surgery (P = 0.001)

1 Year
SAPIEN 3 TAVI
(n = 496)		 Surgery
(n = 454)		 P-Value
All-Cause Death 1.0% 2.5% P = 0.09
All Stroke 1.2% 3.1% P = 0.04
Rehospitalization** 7.3% 11.0% P = 0.046

All-cause death, stroke, and rehospitalization at 1 year: 8.5% TAVI vs. 15.1% for surgery (P = 0.001)

Improved quality of life from baseline†

Low rate of permanent pacemaker

* The PARTNER 3 TRIAL, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.
† Excludes multiplicity adjustment Leon 2019.
** Rehospitalization (valve-related or procedure-related and inclduing heart failure).

Help your patients understand the benefits of TAVI vs surgical aortic valve replacement

View comparison chart

Watch the Edwards SAPIEN 3 Ultra TAVI transfemoral procedure video

Recommended resources

See all resources

Resources for you

Aortic Stenosis Overview Brochure
SAVR vs TAVI Comparison Chart

Resources for your patients

What is TAVI Brochure

Give your patients the best chance at these outcomes and experiences.

Guide them to a Heart Team  for a TAVI evaluation

References:   1. FDA Letter: SAPIEN approval letter 2011. 2. Mack MJ, Leon MB, Thourani VH. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. 3. Fifteen Years of TAVR; Where Are They Now? American College of Cardiology, July 20, 2017. https://www.acc.org/latest-in-cardiology/articles/2017/07/19/15/42/fifteen-years-of-tavr-where-are-we-now. 4. Leon MB, Mack MJ. PARTNER 3: transcatheter or surgical aortic valve replacement in low risk patients with aortic stenosis. Presented at ACC 2019; March 2019; New Orleans, LA. 5. The Partner 3 Trial Clinical Study Report; April 2019.